Imatinib mesylate induces complete cytogenetic response (CCR) in more than 85% of newly chronic myeloid leukemia (CML) chronic phase (CP) patients, and a statistical survival benefit over interferon-a treatment has been recently achieved.
1 Yet, some crucial issues about imatinib are still unsolved and we may refer to this pioneering drug as a 'functional recovery' but not a true cure for CML patients. In fact residual molecular disease persists in the majority of patients 2,3 probably due the in vitro evidence that Ph þ quiescent stem cells are insensitive to imatinib. 4 As a clinical consequence, even in those patients in which BCR-ABL transcript is undetectable by the most sensitive nested reverse transcriptase-PCR method (complete molecular response (CMolR)), discontinuation of the drug is followed by disease recurrence in nearly all cases. 5, 6 Not surprisingly BCR-ABL-positive stem cells can still be detected in patients in CCR after short term of imatinib treatment 7 but no data are currently available regarding the real incidence of leukemic precursors persisting in patients after prolonged treatment with this drug. Thus, we evaluated the amount of bone marrow residual CD34 þ /Ph þ cells in 31 CML patients in stable longlasting CCR during imatinib treatment after receiving their informed written consent. The median age was 46 years (range 19-77) with 18 male and 13 female. At imatinib start all patients were in CP, 15/31 were newly diagnosed while 16/31 have been previously refractory (10 patients) or intolerant (6 patients) to interferon-a. At the time of residual CD34 þ /Ph þ evaluation all patients were on 400 mg/day of imatinib for a median time of 39 months (range 24-59), and in stable CCR for a median time of 35 months (range 15-53). Whole bone marrow fluorescence in situ hybridization (FISH) analysis identified Ph þ cells in 11/31 patients (35%; median of 2% nuclei, range 1-4%), while BCR-ABL transcript was still measurable in 24/31 (77%) patients by reverse transcriptase-PCR.
After immunomagnetic sorting of about 10 ml of marrow aspirate, an adequate number of CD34 þ cells (average 9.6 Â 10 5 ) for FISH analysis was collected in all 31 patients and CD34 þ -enriched population was confirmed to be more than 90% pure by flow cytometry analysis. FISH analysis of CD34 þ -purified cells showed the persistence of Ph þ cells in 14/31 (45%) patients with a median number of 1% (range 1-7%). Disease characteristics and follow-up of 14 CD34 þ / Ph þ positive patients and 17 CD34 þ /Ph þ negative patients are listed in Table 1 .
At the time of evaluation, a weak correlation was found between the persistence of leukemic stem cells and the amount of molecular residual disease. In fact bone marrow fusion transcript was still detectable in 12/14 (86%) CD34 þ / Ph þ positive patients and in 12/17 (70%) CD34 þ / Ph þ negative patients. All patients continued imatinib at 400 mg/day and were monitored for their residual disease. Interestingly, after a median follow-up time of 20 months (range 7-36) since CD34 þ evaluation, 4/14 (28%) patients with residual CD34 þ /Ph þ positive cells showed a significant increase in their molecular disease (considered as more than 1 log increase of BCR-ABL/ABL ratio in two consecutive samples) (Table 1, patient #1, 3, 8, 9) . In addition, one of them lost CCR, while 4/14 (28%) were in stable CMolR. On the contrary, only 2/17 (11%) patients without residual Ph þ stem cells showed an increased level of detectable molecular disease during follow-up (Table 1, patient #20, 28) . No patient in this group lost CCR and 9/17 (53%) were in CMolR.
To our knowledge this is the first 'in vivo' evaluation confirming that CML precursors survive during imatinib treatment even after prolonged and stable CCR. Our findings assessed that at least 45% of these patients harbor residual CD34 þ /Ph þ cells, although the role of these cells in the outcome of imatinib-treated CML patients is not clearly definable from our study. Albeit the series of patients is small we found a trend in a rise of molecular residual disease over time in
Letters to the Editor patients with CD34 þ /Ph þ cells, with potentially a higher risk of cytogenetic relapse. On the other hand at least four patients with documented residual CML precursors achieved a stable CMolR. The co-existence of bone marrow CML precursors and undetectable transcript may reinforce a recent hypothesis indicating a very low level of expression of BCR-ABL of quiescent CML cells. 8 In further studies, the evidence that CML stem cells may be documented by FISH analysis, even in the absence of detectable level of BCR-ABL, may identify not only a new role for molecular cytogenetics in the quantification but also characterization of the cell compartment resistant to imatinib, potential source of disease relapse. Magnetic labeling and separation of CD34+ progenitors was performed on bone marrow mononuclear cells (BMMCs) separated by density gradient. CD34+ cells were selected from BMMCs using immunomagnetic column separation according to published methods and manufacturer instructions (Miltenyi Biotech, Auburn, CA, USA) (17 patients). In order to achieve a highly purified CD34+ population, two rounds of magnetic separation were performed. FISH analysis of whole bone marrow cells and purified CD34+ cells was performed on fixed cells according to conventional published methods and manufacturer's specifications. LSI BCR/ABL Dual color extra signal (ES), single fusion translocation was used as probe (Vysis, Downers Grove, IL, USA). Slides were analyzed with a Nikon 2 fluorescence microscope and images captured with a CCD camera using image analysis system (Genikon, Plano, TX, USA). When conventional bone marrow FISH analysis was performed, at least 300 interphase cells were analyzed independently by two different observers, while for purified CD34+ cells a minimum of 100 interphase nuclei per each sample were evaluated. We scored only isolated cells to avoid possible false positive results (overlapping nuclei) and in addition, 300 peripheral blood cells from five healthy donors were scored as negative internal controls. Thus in our experience the LSI BCR-ABL ES probe has a false positive signal rate close to 0. In acute myeloid leukemia (AML), t(8;21)(q22;q22) translocation is one of the most common karyotype abnormalities, occurring in 7-8% of adult patients. 1 This change is closely associated with AML-M2 subtype in the French-American-British (FAB) classification, a type of AML with high complete remission (CR) rate (85-90%) and favorable survival rate.
1-3 Studies conducted in western countries have demonstrated that survival is prolonged when consolidation chemotherapies comprising high-dose cytarabine are administered.
2
A research group from the Cancer and Leukemia Group B reported that clinical characteristics of t(8;21) AML could alter depending on ethnicity, suggesting that direct adoption of treatment strategies based on clinical studies conducted in western countries to Japanese patients may not be advisable.
4
A recent study from Japan focused mainly on the clinical impact of cytogenetics.
5 Information on clinical characteristics and optimal treatments, such as the clinical impact of high-dose cytarabine, thus remains unavailable for Japanese patients.
To establish optimal therapeutic strategies applicable to Japanese patients, clarification of clinical characteristics and outcomes in Japanese patients with t(8;21) AML is crucial. The present retrospective multicenter study was conducted to investigate the clinical characteristics of Japanese patients with t(8;21) AML.
From January 2000 to December 2005, a total of 147 Japanese adult patients (X15-years-old), who were newly diagnosed with de novo AML (FAB: M2) according to FAB classifications, were consecutively enrolled in nine collaborating hospitals. We retrospectively reviewed the medical records of these patients. These 147 patients included 46 patients with t(8;21) AML and 101 AML(M2) patients without t(8;21).
Diagnosis of t(8;21) AML was established based on chromosomal analysis (G-banding, n ¼ 45) and/or detection of RUN-X1(AML1)/MTG8(ETO) fusion gene by real-time reverse transcription-polymerase chain reaction (n ¼ 16). Overall survival was calculated from diagnosis to death from any causes and event-free survival was defined as the time from diagnosis to the following events: first relapse of AML; treatment-failure; or death from any cause except leukemia. High-, standard-and low-dose cytarabine were defined as X2 g/m 2 /day, 100-200 mg/m 2 /day and p40 mg/m 2 /day, respectively. No patients received any other doses of cytarabine. Of the 46 patients with t(8;21), 4 were enrolled in the AML 202 study of the Japan Adult Leukemia Study Group.
Overall survival rate was calculated using the Kaplan-Meier product limit method. A log-rank test was applied to assess impact by the factor of interest when appropriate. Estimated survival was calculated as of January 31, 2007. Uni-and multivariate Cox proportional hazard models were applied to estimate the impact of potential prognostic factors. Factors associated with at least borderline significance (Po0.10) in univariate analyses were subjected to multivariate analysis using backward stepwise proportional-hazard modeling. Values of Po0.05 were considered statistically significant. Multivariate Cox proportional hazard models were used to determine the influence of age, sex and karyotype (with or without t(8;21)) on survival of all 147 patients. All analyses were conducted using STATA version 9.2 software (STATA, College Station, TX, USA).
Characteristics of AML patients with t(8;21) are shown in Table 1 . Patients with t(8;21) (median age, 49.5 years; range, 18-86 years) were significantly younger than AML(M2) patients without t(8;21) (median age, 60 years; range 17-90 years; Po0.001). AML(M2) patients without t(8;21) included 57 men and 44 women. The median follow-up of surviving patients was 27.0 months (range, 0.2-82.6 months) after diagnosis.
Twelve patients with t(8;21) AML died during follow-up at a median of 10.6 months (range, 3.1-80.1 months) after diagnosis due to primary disease (n ¼ 10), pneumonia (n ¼ 1) or sudden cardiac death (n ¼ 1). Overall survival rates at 3 years after diagnosis in patients with t(8;21) was 70% (95% confidence
